NVN Liquidation Inc (NOVNQ)
0.00
0.00 (0.00%)
USD |
OTCM |
Apr 30, 16:00
NVN Liquidation Cash from Financing (TTM): 19.55M for March 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2023 | 19.55M |
December 31, 2022 | 16.02M |
September 30, 2022 | 5.39M |
June 30, 2022 | 15.25M |
March 31, 2022 | 37.87M |
December 31, 2021 | 44.09M |
September 30, 2021 | 46.12M |
June 30, 2021 | 61.13M |
March 31, 2021 | 43.76M |
December 31, 2020 | 52.81M |
September 30, 2020 | 51.32M |
June 30, 2020 | 36.68M |
March 31, 2020 | 41.65M |
Date | Value |
---|---|
December 31, 2019 | 25.82M |
September 30, 2019 | 25.27M |
June 30, 2019 | 25.02M |
March 31, 2019 | -0.001M |
December 31, 2018 | 35.35M |
September 30, 2018 | 35.22M |
June 30, 2018 | 35.22M |
March 31, 2018 | 35.26M |
December 31, 2017 | -0.088M |
September 30, 2017 | -1.735M |
June 30, 2017 | 45.70M |
March 31, 2017 | 45.26M |
December 31, 2016 | 44.31M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
5.39M
Minimum
Sep 2022
61.13M
Maximum
Jun 2021
34.24M
Average
37.28M
Median
Cash from Financing (TTM) Benchmarks
Cantabio Pharmaceuticals Inc | 1.055M |
Q BioMed Inc | 0.8491M |
Affymax Inc | -- |
Scopus BioPharma Inc | 2.217M |
Statera BioPharma Inc | -1.597M |